Trial Profile
TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer [TH versus THL]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TH v THL
- 17 May 2023 This trial has been completed in Ireland, Germany, Finland, Italy and suspended in Portugal and Spain, no longer in GB according to European Clinical Trials Database record.
- 05 Apr 2023 Status changed from active, no longer recruiting to completed.
- 12 Feb 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.